Retatrutide
Triple GIP / GLP-1 / Glucagon Agonist
Retatrutide is a novel single-molecule triple agonist targeting GIP, GLP-1 and glucagon receptors. The glucagon receptor component provides an additional layer of metabolic research signalling beyond dual agonists.
Mechanism of Action
- •GIP + GLP-1 activity as seen in dual agonists
- •Glucagon receptor engagement increases basal metabolic rate in research models
- •Modulates hepatic glucose output and lipid oxidation pathways
Research Background
- •Phase 2 clinical data published in NEJM (2023) — advanced metabolic research compound
- •Extensive preclinical receptor-binding studies
